(VIANEWS) – GUERBET (GBT.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| GUERBET (GBT.PA) | €32.85 | 1.38% | 8.14% |
| IBA (IBAB.BR) | €14.44 | 1.13% | 8.86% |
| EUROFINS SCIENT. (ERF.PA) | €59.08 | 0.9% | 7.27% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. GUERBET (GBT.PA)
1.38% Forward Dividend Yield and 8.14% Return On Equity
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.
Earnings Per Share
As for profitability, GUERBET has a trailing twelve months EPS of €-3.35.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.14%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 1, 2024, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 1.38%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GUERBET’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 840.79M for the twelve trailing months.
Moving Average
GUERBET’s value is below its 50-day moving average of €34.77 and under its 200-day moving average of €32.85.
More news about GUERBET.
2. IBA (IBAB.BR)
1.13% Forward Dividend Yield and 8.86% Return On Equity
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.27.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 53.48. Meaning, the purchaser of the share is investing €53.48 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.86%.
Yearly Top and Bottom Value
IBA’s stock is valued at €14.44 at 12:30 EST, below its 52-week high of €15.14 and way above its 52-week low of €8.26.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 27, 2024, the estimated forward annual dividend rate is 0.17 and the estimated forward annual dividend yield is 1.13%.
More news about IBA.
3. EUROFINS SCIENT. (ERF.PA)
0.9% Forward Dividend Yield and 7.27% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.27%.
Moving Average
EUROFINS SCIENT.’s value is way above its 50-day moving average of €53.34 and higher than its 200-day moving average of €54.68.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 3, 2024, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 0.9%.
Yearly Top and Bottom Value
EUROFINS SCIENT.’s stock is valued at €59.08 at 12:30 EST, under its 52-week high of €62.10 and way higher than its 52-week low of €39.47.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 6.72B for the twelve trailing months.
More news about EUROFINS SCIENT..
